« Back
Home /
BMS-986299

BMS-986299

Item no.	HY-139396-100mg
Manufacturer	MedChem Express
CASRN	2242952-69-6
Amount	100 mg
Quantity options	100 mg 10mM/1mL 10 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	99.76
Formula	C18H19N7O
Citations	[1]Gary Glick, et al. Substituted imidazo-quinolines as nlrp3 modulators. WO2018152396A1.<br/>[2]Gao G, et al., Cyclovirobuxine D Ameliorates Experimental Diabetic Cardiomyopathy by Inhibiting Cardiomyocyte Pyroptosis via NLRP3 in vivo and in vitro. Front Pharmacol. 2022 Jul 5;13:906548.
Smiles	O=C(C)N(CC)CC1=NC2=C(N1)C3=C(C=C(C4=NNC=C4)C=C3)N=C2N
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Available
Product Description	BMS-986299 (compound 112) is a first-in-class NLRP3 inflammasome agonist with an EC50 of 1.28 μM. (patent WO2018152396A1).
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	349.39
Clinical Information	Phase 1
Manufacturers Research Area	Cancer; Inflammation/Immunology
Solubility	DMSO : 33.33 mg/mL (ultrasonic)
Target	NOD-like Receptor (NLR)
Manufacturers Target	NOD-like Receptor (NLR)
Isoform	NLRP3
Manufacturers Pathway	Immunology/Inflammation
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Request delivery time